NYSE Initiates Delisting Procedures Against Vicarious Surgical
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy RBOT?
The New York Stock Exchange announced that it will commence delisting procedures against Vicarious Surgical.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RBOT
About RBOT
Vicarious Surgical Inc. is a robotics company, developing technology to improve surgical procedures. The Company is combining advanced miniaturized robotics, computer science, sensing and three-dimensional (3D) visualization to build a single-port surgical robot, called the Vicarious Surgical System, that helps surgeons to perform minimally invasive surgery. The Vicarious Surgical System is capable of incision sizes of approximately 1.8 centimeters. The Vicarious Surgical System consists of a camera and instrument arms, surgeon console and patient cart. The Vicarious Surgical System has a high-performance stereoscopic camera that, when combined with robotic motion, provides full 360-degree viewing capability and is being developed to continuously map the depth of the abdominal cavity. The Vicarious Surgical System surgeon console is designed to provide all the systems necessary for the surgeon in visualizing the surgical field and controlling all the motions of the robot.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vicarious Surgical Reports Q4 Loss, Updates Cash Burn Guidance
- Earnings Miss: Vicarious Surgical reported a Q4 non-GAAP EPS of -$1.65, missing expectations by $0.28, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $9.8 million in cash and investments, which, while relatively low, supports short-term operations and reflects urgency in financial management.
- Cash Burn Rate: The cash burn rate for 2025 was $45.1 million, below the initial guidance of $50 million, indicating some progress in cost control that may lay the groundwork for future financial stability.
- Future Guidance: Vicarious Surgical updated its cash burn guidance for 2026 to approximately $19 million, demonstrating optimism regarding operational efficiency improvements and future financial health.
See More
Vicarious Surgical Completes In-Vivo Lab in December 2025, Advancing Robotic Surgery System Development
- Successful Lab Testing: Vicarious Surgical completed an in-vivo lab with porcine models in December 2025, marking a significant advancement in the development of its robotic surgery system, which is expected to facilitate a design freeze by the end of 2026.
- Key Procedure Evaluation: During the lab, surgeons independently performed critical elements of a ventral hernia repair, validating the feasibility of the pre-DV system and providing essential data for future design decisions.
- System Performance Assessment: The lab included three independent development protocols that evaluated core system capabilities such as instrument articulation, visualization, and system integration in a realistic surgical environment, ensuring minimized technical risks.
- Data-Driven Optimization: The data generated and surgeon feedback from the lab will be incorporated into ongoing design refinement and verification planning, further advancing Vicarious Surgical's innovations in minimally invasive surgery.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
- Strategic Partnership Agreement: Vicarious Surgical has entered into a partnership with a global digital engineering firm to reduce operating costs and enhance development predictability and execution efficiency through a more effective mix of internal and external engineering resources.
- Software Development Outsourcing: Under the agreement, the external partner will take on significant software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, which is expected to accelerate development speed and lower structural costs.
- Operational Model Transformation: This collaboration allows internal teams to focus on core innovation and system integration, thereby improving the company's progress toward design freeze and clinical readiness while optimizing its cost structure.
- Ongoing Transition Plan: The external engineering partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams, supporting the company's predictable progress toward key milestones.
See More
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
- Strategic Partnership: Vicarious Surgical has entered into a strategic partnership with a global digital engineering firm, aiming to lower operating costs through an efficient mix of internal and external engineering resources, which is expected to significantly improve the company's cash burn guidance.
- Software Development Outsourcing: Under the agreement, the external partner will take on key software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, thereby enhancing development velocity and milestone predictability.
- Operational Model Transformation: This partnership is a central component of the company's broader operational model transformation, designed to improve execution efficiency and streamline development pathways, which is expected to support more predictable progress.
- Focus on Core Innovation: By partnering with an organization experienced in managing similar complex projects, Vicarious Surgical can concentrate its internal teams on core innovation and system integration, accelerating the timeline toward design freeze and clinical readiness.
See More
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.
Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.
Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.
See More
Vicarious Surgical Reports Q4 Loss, Updates Cash Burn Guidance
- Earnings Miss: Vicarious Surgical reported a Q4 non-GAAP EPS of -$1.65, missing expectations by $0.28, indicating challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, the company had $9.8 million in cash and investments, which, while relatively low, supports short-term operations and reflects urgency in financial management.
- Cash Burn Rate: The cash burn rate for 2025 was $45.1 million, below the initial guidance of $50 million, indicating some progress in cost control that may lay the groundwork for future financial stability.
- Future Guidance: Vicarious Surgical updated its cash burn guidance for 2026 to approximately $19 million, demonstrating optimism regarding operational efficiency improvements and future financial health.
See More
Vicarious Surgical Completes In-Vivo Lab in December 2025, Advancing Robotic Surgery System Development
- Successful Lab Testing: Vicarious Surgical completed an in-vivo lab with porcine models in December 2025, marking a significant advancement in the development of its robotic surgery system, which is expected to facilitate a design freeze by the end of 2026.
- Key Procedure Evaluation: During the lab, surgeons independently performed critical elements of a ventral hernia repair, validating the feasibility of the pre-DV system and providing essential data for future design decisions.
- System Performance Assessment: The lab included three independent development protocols that evaluated core system capabilities such as instrument articulation, visualization, and system integration in a realistic surgical environment, ensuring minimized technical risks.
- Data-Driven Optimization: The data generated and surgeon feedback from the lab will be incorporated into ongoing design refinement and verification planning, further advancing Vicarious Surgical's innovations in minimally invasive surgery.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
- Strategic Partnership Agreement: Vicarious Surgical has entered into a partnership with a global digital engineering firm to reduce operating costs and enhance development predictability and execution efficiency through a more effective mix of internal and external engineering resources.
- Software Development Outsourcing: Under the agreement, the external partner will take on significant software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, which is expected to accelerate development speed and lower structural costs.
- Operational Model Transformation: This collaboration allows internal teams to focus on core innovation and system integration, thereby improving the company's progress toward design freeze and clinical readiness while optimizing its cost structure.
- Ongoing Transition Plan: The external engineering partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams, supporting the company's predictable progress toward key milestones.
See More
Vicarious Surgical Partners with Global Engineering Firm to Enhance Development Efficiency
- Strategic Partnership: Vicarious Surgical has entered into a strategic partnership with a global digital engineering firm, aiming to lower operating costs through an efficient mix of internal and external engineering resources, which is expected to significantly improve the company's cash burn guidance.
- Software Development Outsourcing: Under the agreement, the external partner will take on key software development responsibilities for the Vicarious Surgical robotic system, including control systems and visualization components, thereby enhancing development velocity and milestone predictability.
- Operational Model Transformation: This partnership is a central component of the company's broader operational model transformation, designed to improve execution efficiency and streamline development pathways, which is expected to support more predictable progress.
- Focus on Core Innovation: By partnering with an organization experienced in managing similar complex projects, Vicarious Surgical can concentrate its internal teams on core innovation and system integration, accelerating the timeline toward design freeze and clinical readiness.
See More
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading
UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.
Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.
Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.
See More
